Tennessee school vouchers: Half of applicants request scholarships with income cap
As of May 19, more than 38,000 people applied for the newly launched vouchers, known as Education Freedom Scholarships, just four days after applications opened, a news release from the department stated. The program marks a statewide expansion to Tennessee's controversial school vouchers and offers 20,000 scholarships worth $7,295 for the 2025-26 school year.
The first 10,000 are reserved for families who fall below an income threshold, have children with disabilities or received vouchers under Tennessee's previous program. The remaining 10,000 are open to all eligible students, regardless of income.
The department said it received 18,852 applications for qualified income scholarships and 19,308 for universal scholarships as of May 19. It was not immediately clear if any applicants have been approved, including those who applied for the income-restricted scholarships.
"The demand for universal school choice in Tennessee is strong, and families are embracing the freedom they have been provided through the Education Freedom Scholarship Program," Tennessee Commissioner of Education Lizzette Reynolds said in the release. "All students deserve the ability to access a learning environment that best fits their unique needs."
The applicants so far span 300 zip codes, the release said. An average of 2,935 applications were submitted per grade level from kindergarten through 12th grade.
Applications were still open as of May 20. They will be approved in the order they are received, but it will take some time for the department to process, approve and award the 20,000 vouchers, the release said. A waiting list will be established if additional scholarships become available. Applicants will receive updates from the email address Notifications@TheoLearning.com.
More: TN private school voucher program gets over 33K applications for 20K spots within hours of opening
As applications launched last week, parents reported mixed results on wait times, with some who were in the queue for hours as estimated wait times fluctuated wildly. Others were able to get through in a matter of minutes. Some said they received confirmation emails with the wrong child's name, but later received updates with the correct information. The department said it tested its website and system thoroughly to handle a large influx of traffic ahead of opening applications.
It was not immediately clear when applications will close. Applications and more information can be found at TN.gov/education/EFS.
Rachel Wegner covers education and children's issues for The Tennessean. Got a story you think she should hear? Reach her via email at RAwegner@tennessean.com. You can also find her on Twitter or Bluesky under the handle @RachelAnnWegner.
This article originally appeared on Nashville Tennessean: Tennessee school vouchers: How many listed income restrictions
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
01-07-2025
- Yahoo
CARMAT Announces Its Placement in Receivership Procedure
Resumption of CARMAT shares trading starting July 2, 2025, at stock market opening PARIS, July 01, 2025--(BUSINESS WIRE)--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the "Company" or "CARMAT"), today announces its placement in receivership procedure1 as well as the resumption of CARMAT shares trading, starting July 2, 2025, at stock market opening. Opening of receivership procedure On June 30, 2025, CARMAT had announced in a press release filing for insolvency and requesting to be placed in receivership to the Versailles Economic Affairs Court (the "Court"). Following a hearing held on July 1, 2025, the Court has effectively decided to place CARMAT in receivership. CARMAT's operations carry on during the observation period, in accordance with legal provisions. During this period, CARMAT will assess all options to ensure the continuation of its business activities, notably a disposal plan2. The Company also confirms that it will endeavor to provide continuous support to patients who currently benefit from its Aeson® artificial heart. Press releases will be issued regularly as the Company's situation evolves and the proceedings progress. Resumption of CARMAT shares trading (ISIN code: FR0010907956, Ticker: ALCAR) CARMAT has asked Euronext to resume the trading of its shares starting July 2, 2025, at stock market opening. ●●● About CARMAT CARMAT is a French MedTech that designs, manufactures and markets the Aeson® artificial heart. The Company's ambition is to make Aeson® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world's first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d'Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956). For more information, please go to and follow us on LinkedIn. Name: CARMATISIN code: FR0010907956Ticker: ALCAR ●●● Disclaimer This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe, for CARMAT shares in any country. This press release may contain forward-looking statements regarding the Company's objectives and outlook. These forward-looking statements are based on the current estimates and anticipations of the Company's management and are subject to risk factors and uncertainties, including those described in its Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers) (the "AMF") under number D.25-0345 (the "2024 Universal Registration Document"), available free of charge on the websites of CARMAT ( and the AMF ( Readers' attention is particularly drawn to the fact that the Company is currently placed in receivership (opened on July 1, 2025) and is facing a very high risk of default, including in the very short term. The Company is also exposed to other risks and uncertainties, such as its ability to implement its strategy, the pace of development of its production and sales, the progress and results of ongoing or planned clinical trials, technological developments, the competitive landscape, regulatory changes, industrial risks, and all risks related to the management of the Company's growth. Forward-looking statements mentioned in this press release may not be achieved due to these factors or other unknown risks and uncertainties, or risks that the Company does not currently consider to be material or specific. Aeson® is an active implantable medical device commercially available in the European Union and other countries recognising the CE mark. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure (Intermacs classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to benefit from a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician's manual, patient's manual and alarm booklet) must be read carefully to learn about the characteristics of Aeson® and the information required for patient selection and proper use (contraindications, precautions, side effects) of Aeson®. In the United States, Aeson® is currently only available as part of a feasibility clinical trial approved by the Food & Drug Administration (FDA). 1 « Redressement judiciaire »2 « Plan de cession » View source version on Contacts CARMAT Stéphane Piat Chief Executive Officer Pascale d'Arbonneau Deputy Chief Executive Officer & Chief Financial OfficerTel.: +33 1 39 45 64 50contact@ NewCap Press Relations Nicolas Merigeau Arthur Rouillé Tel.: +33 1 44 71 94 98carmat@ NewCap Financial Communication& Investor Relations Dusan Oresansky Jérémy Digel Tel.: +33 1 44 71 94 92carmat@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
20-06-2025
- Business Wire
CARMAT Announces Being in a Critical Financial Situation and at Risk of Insolvency as of End-June 2025
PARIS--(BUSINESS WIRE)--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the ' Company ' or ' CARMAT '), today announces being in a critical financial situation and at risk of insolvency as early as the end of June 2025. Critical financial situation and risk of insolvency at the end of June 2025 When reporting its full-year 2024 results (press release dated April 29, 2025), on April 29, 2025, the Company had indicated that it was funded until mid-June 2025 and actively working on financing options to secure, in the short term, the resources needed to continue its operations beyond that date. Despite all its efforts, in a very challenging funding environment—particularly for small and mid-cap companies—the Company has not, to date, been able to secure such financing and will be in a situation of insolvency at the end of June 2025 unless it manages, before then, to secure additional cash of at least €3.5 million. More generally, based on its current business plan, the Company estimates its 12-month financial needs at approximately €35 million, including around €20 million by end-December 2025 (broken down into €8 million by end-July, an additional €4 million by end-September, and a further €8 million by end-December 2025). Next steps and launch of a donation campaign CARMAT continues to actively explore all financing options to ensure business continuity beyond June 2025. In parallel to this, the Company is today launching a donation campaign through an online platform, which is the subject of a separate press release (link to the press release). Press releases will be issued regularly to keep shareholders and the financial community informed of any developments regarding the Company's financial situation. About CARMAT CARMAT is a French MedTech that designs, manufactures and markets the Aeson ® artificial heart. The Company's ambition is to make Aeson ® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world's first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson ® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson ® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson ® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d'Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956). For more information, please go to and follow us on LinkedIn. Disclaimer This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe, for CARMAT shares in any country. This press release may contain forward-looking statements regarding the Company's objectives and outlook. These forward-looking statements are based on the current estimates and anticipations of the Company's management and are subject to risk factors and uncertainties, including those described in its Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers) (the 'AMF') under number D.25-0345 (the ' 2024 Universal Registration Document '), available free of charge on the websites of CARMAT ( and the AMF ( Readers' attention is particularly drawn to the fact that the Company's current cash runway extends only until the end of June 2025, and that CARMAT is therefore facing a very high risk of default, including in the very short term. The Company is also exposed to other risks and uncertainties, such as its ability to implement its strategy, the pace of development of its production and sales, the progress and results of ongoing or planned clinical trials, technological developments, the competitive landscape, regulatory changes, industrial risks, and all risks related to the management of the Company's growth. Forward-looking statements mentioned in this press release may not be achieved due to these factors or other unknown risks and uncertainties, or risks that the Company does not currently consider to be material or specific. Aeson® is an active implantable medical device commercially available in the European Union and other countries recognising the CE mark. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure (Intermacs classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to benefit from a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician's manual, patient's manual and alarm booklet) must be read carefully to learn about the characteristics of Aeson® and the information required for patient selection and proper use (contraindications, precautions, side effects) of Aeson®. In the United States, Aeson® is currently only available as part of a feasibility clinical trial approved by the Food & Drug Administration (FDA).
Yahoo
12-06-2025
- Yahoo
Crisis-hit Croydon Council needs reset, MP says
A "short and sharp reset" is required for Croydon Council to recover from poor performance and high debt levels, the minister for housing, communities and local government has announced. Jim McMahon has told the House of Commons the council's financial position is "deteriorating rapidly" after a report highlighted concerns about its ability to improve. McMahon said that failing to change course "would condemn Croydon's residents to a worsening position without an exit strategy" and he was "minded to" send in commissioners to run the council. Executive mayor of Croydon, Jason Perry, said he and the council "had done everything possible" to fix the finances "whilst protecting vital services". Perry added: "We have generated over £230m in capital receipts, including £130m of asset sales and have plans to sell a further £68m assets this year. "The council also raised council tax by 10% over the cap in 2023, to help meet the panel's demand that we close the gap in the council's finances." The council had been under review by the government's improvement and assurance panel, set up to provide external advice, challenge and expertise. McMahon said the council's general fund debt sits at around £1.4bn and it relies on the allocation of Exceptional Financial Support (EFS) through in-principle capitalisation directions to balance its budget. The panel's report has said there has been a lack of pace throughout the intervention, but the deteriorating financial position, which is not being gripped and tackled adequately by the council, is reaching a "financial crisis". McMahon added: "I am satisfied that the London Borough of Croydon is failing to comply with its Best Value Duty. I am therefore minded to exercise powers of direction under section 15(5) and 15(6) of the Local Government Act 1999 to implement an intervention package." Perry said, via a statement: "If at any time the panel or government felt that there was any action the council should be taking and was not, they had the power to instruct us. They never did. "Surely that means we are doing everything possible, and they agree with our actions? We have already made very difficult decisions and in my view the residents of Croydon have felt enough pain. "Despite all the improvements that have been delivered by the council and its staff, it appears the government wants to centralise control into the hands of commissioners." He said the council would consider all options before submitting its formal response to the government, the deadline for which is 25 June. Listen to the best of BBC Radio London on Sounds and follow BBC London on Facebook, X and Instagram. Send your story ideas to Croydon Council asks for £136m government bailout Council to make cuts to services to save £30m Croydon approves council tax rise of 15%